What is a company worth? This is the question that appraisers and financial experts often need to answer. That is why every informed stakeholder in business valuation, performance benchmarking, or risk assessment turns to Business Valuation Resources (BVR) for authoritative deal and market data, news and research, training, and expert opinion when valuing a business. Trust BVR for unimpeachable business valuation intelligence. BVR’s data, publications, and analysis have won in the boardroom and the courtroom for over two decades. Learn more >>

BVR has resources for many financial professionals, including business appraisers, attorneys, M&A advisors, brokers, business owners, and more. See who turns to our best-in-class tools to support their valuation conclusions. Learn more >>

Yes! I'd like to subscribe to the following ezines to guarantee I am current with the latest happenings in the BV profession.


FEATURED ITEMS

DealStats
FactSet Review Featured Item
Nambri Featured Item

UPCOMING TRAINING

Power Panel: Trends and Issues in Business Valuation

LATEST NEWS

Connecticut court affirms lower court's decision not to tax affect

In a buyout dispute involving a Connecticut family business, an appellate court recently upheld the trial court’s earlier decision not to tax affect the earnings of the company in valuing the departing shareholder’s interest, even though experts for both sides tax affected. Read more >>

Tennessee no longer mandates Delaware block method to determine fair value

For the longest time, Tennessee case law required trial courts presiding over dissenting shareholder actions to determine fair value by using the Delaware block method. In a recent ruling, the Tennessee Supreme Court struck down the requirement and Tennessee has joined the jurisdictions that allow "more modern" valuation approaches. Read more >>

Trial court’s IPO valuation in fair value proceeding holds up on appeal

A recent case shows just how difficult it is to value a startup. Here, there was an extra challenge because the subject was a pharmaceutical venture that required years of funding for the development of two drugs working toward FDA approval. The trial court needed to determine the fair value of the plaintiff’s interest prior to the company’s ultimate success. Read more >>